PT  - JOURNAL ARTICLE
AU  - Joubert, Antoine
AU  - Andry, Fanny
AU  - Bertolotti, Antoine
AU  - Accot, Frédéric
AU  - Koumar, Yatrika
AU  - Legrand, Florian
AU  - Poubeau, Patrice
AU  - Manaquin, Rodolphe
AU  - Gérardin, Patrick
AU  - Levin, Cécile
TI  - Distinguishing non severe cases of dengue from COVID-19 in the context of co-epidemics: a cohort study in a SARS-CoV-2 testing center on Reunion island
AID  - 10.1101/2020.10.20.20214718
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.20.20214718
4099  - http://medrxiv.org/content/early/2020/10/29/2020.10.20.20214718.short
4100  - http://medrxiv.org/content/early/2020/10/29/2020.10.20.20214718.full
AB  - Background As coronavirus (COVID-19) is spreading globally, several countries are handling dengue epidemics. As both infections are deemed to share similarities at presentation, it would be useful to distinguish COVID-19 from dengue in the context of co-epidemics. In this aim, we performed a cohort study to identify predictors of both infections.Methods All the subjects suspected of COVID-19 between March 23 and May 10, 2020, were screened for COVID-19 within the testing center of the University hospital of Saint-Pierre, Reunion island. The screening consisted in a questionnaire surveyed in face-to-face, a nasopharyngeal swab specimen for the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) reverse transcription polymerase chain-reaction and a rapid diagnostic orientation test for dengue. Factors independently associated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls.Results Over a two-month study period, we identified among 80 COVID-19, 60 non-severe dengue and 872 OFIs cases, delayed presentation (>3 days) since symptom onset (Odds ratio 1.89, 95% confidence interval 1.4-3.40), contact with a COVID-19 positive case (OR 3.81, 95%CI 2.12-6.82) and anosmia (OR 8.27, 95%CI 4.39-15.54) as independent predictors of COVID-19, body ache (OR 6.83, 95%CI 2.84-16.41), headache (OR 5.38, 95%CI 1.81-15.94) and retro-orbital pain (OR 7.45, 95%CI 3.17-17.50) as independent predictors of dengue, while smoking was less likely observed with COVID-19 (OR 0.27, 95%CI 0.10-0.74).Conclusions Although prone to potential biases, these data suggest that non-severe dengue may be more symptomatic than COVID-19 in a co-epidemic setting with higher dengue attack rates.40-word summary of the article’s main point In the COVID-19 dengue co-epidemic setting of Reunion island, dengue was found more symptomatic than COVID-19 and associated with body ache, headache and retro-orbital pain, while COVID-19 was found associated with contact, anosmia, delayed presentation and absence of active smoking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding for this study conducted within standard care proceduresAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Outpatients presenting consecutively at the SARS-CoV-2 testing center were informed of the study orally and by means of an information sheet. People who expressed no opposition were asked to answer a questionnaire and surveyed in face-to-face by a nurse, in accordance to the French legislation on bioethics for retrospective researches. Patient medical records were retrospectively reviewed, and all data collected were anonymized in standardized forms according the MR-004 procedure of the CNIL (the French information protection commission).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be processed for the development of a scoring system. After having submitted our second paper, we will provide an access to the data in a data repository according to data sharing. In the meantime, data availability will be discussed on requestCIRcumulative incidence rate (= attack rate)CNRcentre national de referenceCOVID-19coronavirus 2019DENVdengue virusOFIsother febrile illnessesaORadjusted odds ratioRT-PCRreverse transcription – polymerase chain reactionSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2spO2partial saturation of oxygenUDACSunite de dépistage ambulatoire du coronavirus sudURTIupper respiratory tract infection95% CI95% confidence intervals